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Modulation of nociception and inflammation by sulfide in rheumatoid arthritis and activation 
of transient receptor potential ankyrin 1 (TRPA1) ion channels by sulfide compounds are 
well documented. The present study aims to investigate TRPA1-mediated effects of sulfide 
donor GYY4137 in K/BxN serum-transfer arthritis, a rodent model of rheumatoid arthritis. 
TRPA1 and somatostatin sst4 receptor wild-type (WT) and knockout mice underwent K/
BxN serum transfer and were treated daily with GYY4137. Functional and biochemical 
signs of inflammation were recorded, together with histological characterization. These 
included detection of hind paw mechanical hyperalgesia by dynamic plantar esthesiometry, 
hind paw volume by plethysmometry, and upside-down hanging time to failure. Hind 
paw erythema, edema, and passive movement range of tibiotarsal joints were scored. 
Somatostatin release from sensory nerve endings of TRPA1 wild-type and knockout mice 
in response to polysulfide was detected by radioimmunoassay. Polysulfide formation 
from GYY4137 was uncovered by cold cyanolysis. GYY4137 aggravated mechanical 
hyperalgesia in TRPA1 knockout mice but ameliorated it in wild-type ones. Arthritis score 
was lowered by GYY4137 in TRPA1 wild-type animals. Increased myeloperoxidase 
activity, plasma extravasation, and subcutaneous MIP-2 levels of hind paws were detected 
in TRPA1 knockout mice upon GYY4137 treatment. Genetic lack of sst4 receptors did 
not alter mechanical hyperalgesia, edema formation, hanging performance, arthritis 
score, plasma extravasation, or myeloperoxidase activity. TRPA1 WT animals exhibited 
smaller cartilage destruction upon GYY4137 administration. Sodium polysulfide caused 
TRPA1-dependent somatostatin release from murine nerve endings. Sulfide released 
from GYY4137 is readily converted into polysulfide by hypochlorite. Polysulfide potently 
activates human TRPA1 receptors expressed in Chinese hamster ovary (CHO) cells. 
According to our data, the protective effect of GYY4137 is mediated by TRPA1, while 
detrimental actions are independent of the ion channel in the K/BxN serum-transfer 
arthritis model in mice. At acidic pH in inflamed tissue sulfide is released from GYY4137 
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and reacts with neutrophil-derived hypochlorite. Resulting polysulfide might be responsible 
for TRPA1-mediated antinociceptive and anti-inflammatory as well as TRPA1-independent 
pro-inflammatory effects.
Keywords: GYY4137, TRPA1, K/BxN serum-transfer model, arthritis, hydrogen sulphide, polysulfide, 
hypochlorite, MIP-2
INTRODUCTION
Despite a heavy improvement in remissions and disease activity 
due to emerging targeted disease-modifying biologic treatment 
options, adverse drug reactions still make the pharmacotherapy 
of rheumatoid arthritis (RA) a challenging quest for patient and 
physician (Chatzidionysiou et al., 2017; Edwards et al., 2017). 
Animal models of the disease are valuable tools in the search 
for therapeutic targets. The murine K/BxN serum-transfer 
arthritis is a much-preferred model of RA because it is suitable 
for a variety of gene-deficient mouse strains and is extremely 
reliable. Arthritis is induced by intraperitoneal administration of 
serum from genetically arthritic K/BxN animals. Development 
of inflammatory response involves autoantibody formation 
against the enzyme glucose-6-phosphate isomerase and immune 
complex-driven activation of neutrophil granulocytes and 
macrophages. Several cytokines, chemokines, the complement 
system, adhesion molecules, and receptors contribute to the 
molecular pathology. Although glucose-6-phosphate isomerase 
is surely not the major autoantigen in human RA, the K/BxN 
serum-transfer arthritis model is very useful in the investigation 
of the interaction between autoantibodies and the innate immune 
system, as well as inflammatory pain (Christensen et al., 2016).
The gaseous mediator hydrogen sulfide (in the following 
text, the term sulfide denotes H2S, HS−, and S2−) is known to 
play a regulatory role in inflammation. Some authors report 
anti-inflammatory effects of H2S, while others have found 
pro-inflammatory action (Burguera et al., 2017; Muniraj 
et al., 2017). The two kinds of findings might be both true and 
complementary. Inflammation might induce the H2S-producing 
enzyme cystathionine-γ-lyase (CSE) resulting in elevated 
H2S concentration. H2S might contribute to inflammatory 
vasodilatation and might compromise mitochondrial function 
by inhibiting complex IV of the electron transport chain. On the 
other hand, smaller H2S concentration in the mitochondria can 
actually fuel oxidative phosphorylation and mitigate oxidative 
stress (Ahmad and Szabo, 2016). Today, slow-releasing donors 
of sulfide are preferred over inorganic sulfide sources (e.g., 
NaHS and Na2S-nonahydrate). Inorganic salts produce a swift 
but short-lived elevation of sulfide concentration not necessarily 
representing physiological conditions. Slow-releasing donors 
might better mimic the endogenous situation. The two most 
studied donors are GYY4137 and AP39. GYY4137 releases sulfide 
in every tissue, while AP39 is selective to mitochondria, enabling 
the investigation of the protective effects of the gasotransmitter 
(Li et al., 2008; Szczesny et al., 2014).
Transient receptor potential ankyrin 1 (TRPA1) non-selective 
cation channel belongs to transient receptor potential ankyrin 
receptor subfamily of transient receptor potential ion channels. 
It is the sole ankyrin-type TRP channel in mammals. TRPA1 is 
expressed in primary nociceptor neurons and non-neuronal cells 
including joint-related cells (e.g., chondrocytes and synoviocytes) 
and immune cells (Zygmunt and Högestätt, 2014). TRPA1 is 
known to contribute to inflammatory hyperalgesia in murine 
complete Freund’s adjuvant-induced (CFA) arthritis—another 
animal model of human RA (Fernandes et al., 2016; Horváth 
et al., 2016). Expression of TRPA1 channels in peripheral 
blood leukocytes of RA patients was shown to correlate with 
the perceived pain (Pereira et al., 2017). TRPA1 receptors 
can be activated by various stimuli ranging from temperature 
to chemicals. Electrophilic agents excite TRPA1 by forming 
covalent bonds with cysteine residues of the receptor (Zygmunt 
and Högestätt, 2014). Sulfide is able to activate TRPA1 receptors 
(Hajna et al., 2016). This interaction is most probably transmitted 
by polysulfides—originating from sulfide—in concert with 
hypochlorite or nitric oxide (Greiner et al., 2013; Cortese-Krott 
et al., 2015). These characteristics set sulfide in the focus point 
of the modulation of the inflammatory process in RA, marking 
it as a promising drug target. A well-characterized potential 
downstream mechanism of activation of peptidergic nociceptors 
via TRPA1 opening is a consequent release of somatostatin 
(SOM) from the nerve fibers and signaling of sst4 receptors on 
nociceptors and other cell types (Pintér et al., 2006).
The present study was intended to investigate the role of 
sulfide and TRPA1 channels in the murine K/BxN arthritis 
model. The slow-releasing donor of sulfide, GYY4137, was 
administered to TRPA1 wild-type (WT) and knockout (KO) 
animals undergoing serum-evoked polyarthritis. Functional 
parameters of the arthritic changes (e.g., mechanical 
hyperalgesia and grip strength) were evaluated alongside 
with markers of inflammation (e.g., clinical score, plasma 
extravasation, myeloperoxidase (MPO) activity, and cytokine 
concentrations in the affected joints). Similar experiments were 
conducted with mice lacking somatostatin sst4 receptor gene. 
Release of SOM from the isolated skin pieces of TRPA1 WT 
and KO animals due to stimulation with polysulfide (POLY) 
was detected by radioimmunoassay. Formation of POLY from 
GYY4137 upon reaction with hypochlorite was characterized 
by cold cyanolysis.
MATERIALS AND METHODS
Animals
Experiments were carried out on male TRPA1 or sst4 
deficient mice (KO) and on their wild-type counterparts 
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(WT). Both strains were generated on C57BL/6J background. 
The experimental animals were offspring of heterozygous 
parents, and their genotype was determined using real-time 
polymerase chain reaction (PCR) technique. The original 
heterozygous TRPA1 breeding pair was a generous gift from 
Pierangelo Geppetti (University of Florence, Italy). These 
mice were originally generated and characterized by Bautista 
and colleagues (Bautista et al., 2006). Sst4 KO animals were 
generated by Jeremy P. Allen and Piers C. Emson (Helyes et 
al., 2009). The mice were kept and bred in the Laboratory 
Animal House of the Department of Pharmacology and 
Pharmacotherapy at the University of Pécs under standard 
pathogen-free conditions. Standard mouse chow and water 
were provided ad libitum. Temperature was maintained 
between 24°C and 25°C, and the light–dark cycle was set to 
12  h. Mice were housed in groups of 5–10 in polycarbonate 
cages (330-cm2 floor space, 12-cm height) on wood shavings 
bedding. Certificate numbers of the animal breeding 
facilities (Department of Pharmacology and Pharmacotherapy 
and Szentágothai Research Centre, University of Pécs) are 
ZOHU0104L09 and ZOHU0104L03.
Drugs and Chemicals
All chemicals were purchased from Sigma-Aldrich, except 
for the following: ketamine (Calypsol, Gedeon Richter Plc., 
Budapest, Hungary), xylazine (Sedaxylan, Eurovet Animal 
Health B.V., Bladel, the Netherlands), luminol sodium salt (Gold 
Biotechnology, Olivette, MO, USA), and IR-676 (Spectrum-Info 
Ltd., Kyiv, Ukraine). GYY4137 was synthetized at the Department 
of Organic Chemistry, Medical School, University of Pécs, Pécs, 
Hungary, as previously described (Li et al., 2008).
Detection of Polysulfide Formation From 
GYY4137 by Cold Cyanolysis
GYY4137 was dissolved in distilled water (7.95 mmol L−1), and 
equal volume of citrate buffer (100 mmol L−1, pH 3.0) was added. 
The mixture was incubated for 90  min, and equal volume of 
hypochlorous acid (200  μmol  L−1) was added. Cold cyanolysis 
was performed as described earlier (Wood, 1987). The mixture 
of hypochlorous acid and GYY4137 was alkalized and reacted 
with KCN. Formaldehyde and Goldstein reagent (Bátai et al., 
2018) were added, and absorbance was detected at 460 nm. POLY 
concentration was calculated according to a standard curve 
constructed with KSCN.
Measurement of Ca2+ Influx Into CHO Cells 
Expressing Human TRPA1 in Response 
to GYY4137 and Hypochlorous Acid by 
Flow Cytometry
Chinese hamster ovary (CHO) cells were transfected with 
human TRPA1, as described earlier (Pozsgai et al., 2017). 
Human TRPA1 cDNA clone was purchased from Life 
Technologies CloneRanger collection (clone ID: 100016279). 
The cDNA was inserted between the cytomegalovirus (CMV) 
promoter and the bovine growth hormone polyA region 
in pT3CMV vector. pT3CMV originates from the pT2/BH 
Sleeping Beauty transposon vector (Addgene, ID: 26556) with 
neomycin expression cassette. CHO cells were co-transfected 
with vectors containing human TRPA1 and the pCMVSB100x 
vector carrying the transposase. Successful clones were selected 
in medium containing G418 (500  μg  mL−1). After trypsin 
treatment, cells were loaded with Fluo-4 AM (Invitrogen) 
for 30  min at 37°C. Extracellular solution (ECS) was added 
(400 μL, containing in mmol L−1: NaCl, 160; KCl, 2.5; CaCl2, 
1; MgCl2, 2; HEPES, 10; glucose, 10; pH 7.3). Sodium sulfide 
nonahydrate (Na2S·9H2O) was dissolved in Millipore water. 
Tubes used were previously filled with nitrogen. Concentration 
of the solution was measured by detecting light absorption 
at 230  nm (based on E230  =  7,700  L  mol−1  cm−1), as well as 
adding 5,5′-dithiobis(2-nitrobenzoic acid) and measuring 
light absorption at 412  nm. A concentration response curve 
was constructed using various concentrations of sodium 
sulfide nonahydrate. GYY4137 was dissolved in distilled water 
(3 mg mL−1, 7.95 mmol L−1). GYY4137 was diluted further in 
ECS buffer, and a concentration–response curve was produced. 
POLY (10 μmol L−1 in ECS) was added to the cell suspensions, 
too. POLY was prepared as described earlier (Bátai et al., 
2018). Stock solutions of hypochlorous acid and sodium 
sulfide nonahydrate were prepared in distilled water using 
polypropylene tubes blown with nitrogen gas. Stock solutions 
were aliquoted and stored at −20°C. Sulfide stock solution 
was diluted in distilled water to 60  mmol  L−1. Hypochlorous 
acid solution was added slowly to produce 20  mmol  L−1 
concentration. The resulting POLY solution was diluted two-
fold in distilled water containing 4.17% v/v 10× concentrated 
phosphate-buffered saline (PBS, pH 7.4). Concentrated 
hydrochloric acid was then added gradually to set the pH to 
7.4. This POLY solution was diluted further in ECS buffer. 
Sulfide and POLY solutions were kept on ice and were protected 
from direct light. We examined if polysulfide resulting from 
the reaction GYY4137-released sulfide and hypochlorous acid 
activates TRPA1 ion channels in CHO cells. Allyl isothiocyanate 
(100  μmol  L−1) was used as positive control. GYY4137 was 
dissolved in distilled water (3 mg mL−1, 7.95 mmol L−1). Equal 
volume of hydrochloric acid (1  mmol  L−1) was added, and 
the mixture was incubated at room temperature in the dark 
for 120 min. Sulfide released from GYY4137 was determined 
with 5,5′-dithiobis(2-nitrobenzoic acid) as described above. 
Hypochlorous acid (616  μmol  L−1 final concentration in the 
mixture) was added to convert sulfide into POLY. Respective 
concentrations of hypochlorous acid and GYY4137 were 
tested separately in TRPA1-expressing CHO cells. The mixture 
of acidified GYY4137 and hypochlorous acid was examined 
using CHO cells expressing human TRPA1 ion channels and 
untransfected ones. Cell suspensions were analyzed by flow 
cytometry. Fluo-4 AM was excited at 488 nm, and fluorescence 
was detected at 504  nm. Mean green fluorescence of the 
samples was compared with base fluorescence of dye-loaded 
control cells, resulting in a baseline value of 1. Some cell groups 
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were pre-incubated with selective TRPA1 receptor antagonist 
HC-030031 (50 μmol L−1 in ECS) for 5 min. Flow cytometry 
experiments were performed at room temperature.
Detection of Somatostatin Release 
From Murine Nerve Endings by 
Radioimmunoassay
POLY was prepared as described above (Nagy and Winterbourn, 
2010; Bátai et al., 2018). POLY solution was diluted in distilled 
water to yield 10 μmol L−1 in the organ bath.
TRPA1 WT and KO mice were sacrificed by cervical 
dislocation. Hind legs were shaved by a fine clipper. The skin 
was removed and placed in oxygenated synthetic interstitial 
fluid (SIF; composition in mmol  L−1: NaCl 107.8, NaHCO3 
26.2, sodium gluconate 9.64, sucrose 7.6, glucose 5.05, KCl 
3.48, NaH2PO4 1.67, CaCl2 1.53, and MgSO4 0.69) at room 
temperature. Skin samples were fixed inside-out on acrylic 
rods by sutures and were transferred to 37°C oxygenated SIF 
solution in a shaking bath. After being shaken for 30  min, 
samples were transferred into glass test tubes containing 800 μL 
of SIF for 5  min. Then samples were forwarded into a new 
series of similar tubes containing 10 μmol L−1 of POLY in SIF 
for 5 min, and previous incubating solutions were harvested. 
Finally, the samples were placed into other tubes containing 
800 μL of SIF for another 5 min. POLY-containing and final 
incubating solutions were harvested, too. The solutions of the 
first series were evaluated for basal, the ones from the second 
series for stimulated, and the ones of the third series for post-
stimulated SOM release. In some experiments, stimulated and 
post-stimulated fractions contained 50 μmol L−1 of HC-030031 
(Pozsgai et al., 2017). Wet weight of skin samples was taken 
after experiments. Radioimmunoassay was performed to 
detect somatostatin-like immunoreactivity in the incubating 
solutions as described earlier (Pozsgai et al., 2017). Shortly, 
phosphate buffer (pH 7.4, 50  mmol  L−1) containing sodium 
chloride (100 mmol L−1), sodium azide (0.05% w/v), and bovine 
serum albumin (0.25% w/v) was used for the assay. The assay 
includes samples or standard peptides, tracer, and antiserum. 
Somatostatin-14 was used as standard. Tracer was produced 
from (Tyr1)-somatostatin-14 by iodinating the peptide with 
Na125I. Iodination is catalyzed by 1,3,4,6-tetrachloro-3α,6α-
diphenylglycouril. Antiserum has been raised in sheep against 
somatostatin-14–bovine thyroglobulin. Antiserum was 
diluted 1:260,000. Immune complexes and free peptides were 
separated by Norit-A (10% w/v), dextran (molecular weight 
[MW]: 65–73  kDa, 1% w/v), and commercial fat-free milk 
powder (0.2% w/v) in distilled water. Radioactivity of both 
free peptides and immune complexes were detected (Gamma 
NZ-310, Hungary). Standard curve was generated by plotting 
the ratio of the activity of pellets and activity of supernatants 
of standard samples. Results are expressed as total SOM-like 
immunoreactivity (fmol SOM-LI) per milligram wet skin. 
Total SOM-LI is made up of the sum of stimulated and post-
stimulated values with basal release values subtracted from 
each value.
In Vivo Luminescence and Fluorescence 
Imaging
In the K/BxN serum-transfer arthritis model, i.p. luminol sodium 
salt (5-amino-2,3-dihydro-1,4-phthalazine-dione; 150  mg  kg−1) 
dissolved in sterile PBS (30 mg mL−1) was used to detect production 
of reactive oxygen species (ROS) correlated with neutrophil MPO 
activity. Furthermore, i.v. IR-676 (0.5  mg  kg−1) fluorescent dye 
dissolved in aqueous solution of Kolliphor HS 15 (5% v/v) was used 
to assess plasma protein extravasation 0, 2, and 6 days following 
serum administration (Botz et al., 2014). Mice were anesthetized 
by ketamine/xylazine (120/12 mg kg−1 i.p.). Bioluminescence was 
measured for 10 min and fluorescence 20 min postinjection using 
the IVIS Lumina II (PerkinElmer, Waltham, USA; 120-s acquisition, 
F/stop = 1, binning = 8 in bioluminescence; auto acquisition time, 
F/stop = 1, binning = 2, excitation/emission filter 640/700 nm in 
fluorescence). Living Image® software (PerkinElmer, Waltham, 
USA) was used. Identical region of interests (ROIs) were drawn 
around both ankle joints; then calibrated units of luminescence 
(total radiance  =  total photon flux  s−1) and fluorescence (total 
radiant efficiency  =  (photons  s−1)(μW  cm−2)−1) originating from 
the ROIs were analyzed (Borbély et al., 2015).
K/BxN Serum-Transfer Model of 
Autoimmune Arthritis
Kouskoff et al. generated the K/BxN spontaneously arthritic 
mouse strain with distinct features representing human 
rheumatoid arthritis (Kouskoff et al., 1996). Transferring sera 
from K/BxN mice into non-arthritic mouse strains results 
in a similar arthritic condition as described in the donor K/
BxN strain. In a comprehensive review, Christensen et al. 
summarized the underlying pathogenesis and distinct features 
of the K/BxN serum-transfer arthritis model (Christensen et 
al., 2016). Briefly, in our protocol, serum-transfer arthritis was 
induced by a single intraperitoneal injection of 300 μL of serum 
acquired from K/BxN mice. The non-arthritogenic control 
serum was obtained from BxN mice. Prior to the induction 
of arthritis, mice received a single treatment of slow-releasing 
sulfide donor GYY4137 or PBS. The treatment with GYY4137 
(50 mg kg−1 day−1) or PBS was continued daily for 7 days after 
serum transfer. The intraperitoneal administration of GYY4137 
or vehicle always preceded the scoring, functional tests, and 
in vivo imaging by 1  h. The following experimental animal 
groups were examined: 1) K/BxN serum-treated arthritic 
TRPA1 WT mice injected daily with vehicle of GYY4137 
(PBS) participating in dynamic plantar esthesiometry, drop 
latency testing, plethysmometry, scoring, and luminescence 
and fluorescence imaging to detect myeloperoxidase activity 
and plasma extravasation, as well as histological processing 
of tibiotarsal joints; 2) TRPA1 KO mice receiving K/BxN 
serum, identical vehicle treatment, and evaluation; 3) K/
BxN serum-injected sst4 receptor WT animals administered 
vehicle undergoing the above experimental processes; 4) 
sst4 KO mice treated with K/BxN serum and vehicle used in 
similar experiments; 5) K/BxN serum-treated arthritic TRPA1 
WT mice injected daily with GYY4137 (50  mg  kg−1  day−1) 
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undergoing dynamic plantar esthesiometry, drop latency 
testing, plethysmometry, scoring, and luminescence and 
fluorescence imaging to detect myeloperoxidase activity and 
plasma extravasation, as well as histological processing of 
tibiotarsal joints; 6) TRPA1 KO animals treated with K/BxN 
serum and GYY4137 (50 mg kg−1 day−1) participating in the 
above experiments; 7) K/BxN serum-injected sst4 receptor 
WT mice receiving GYY4137 (50  mg  kg−1  day−1) and used 
in the above experimental settings; 8) K/BxN serum-treated 
sst4 KO animals injected with GYY4137 (50  mg  kg−1  day−1) 
undergoing identical processes; 9) K/BxN serum-injected 
TRPA1 WT mice administered vehicle of GYY4137 (PBS) daily 
utilized to collect subcutaneous lavage fluid from inflamed 
hind paws for cytokine detection; 10) TRPA1 KO mice treated 
with K/BxN serum and vehicle used to collect lavage fluid; 
11) K/BxN serum-injected TRPA1 WT mice administered 
GYY4137 (50  mg  kg−1  day−1) used to collect subcutaneous 
lavage fluid from inflamed hind paws for cytokine detection; 
12) K/BxN serum-treated TRPA1 KO mice administered 
GYY4137 used to collect lavage samples of the hind paws; 
and 13–24) the above treatments were performed on non-
arthritic control animals injected with BxN serum to validate 
the serum-transfer arthritis model. Figure 1 gives a schematic 
representation of the treatment groups.
Dynamic Plantar Esthesiometry
Mechanical hyperalgesia of the hind paws was determined 
by dynamic plantar aesthesiometry (DPA, Ugo Basile 37400, 
Comerio, Italy). The measurements were performed on 
three separate days prior to induction of serum-transfer 
arthritis and thereafter on days 3, 5, and 7. A maximum force 
equivalent to 10 g with a 4-s latency was applied to the hind 
paws. Mechanical hyperalgesia was defined as decrease of 
mechanical pain threshold compared with baseline (average of 
the three measurements before induction of arthritis) and was 
 expressed in grams.
Drop Latency/Grip Test
To assess the function of the joints and the overall stamina of 
the animals, a simple grip test was performed on days 3, 5, and 
7. Mice were placed on a wire grid, which was then lifted up in 
horizontal position and rotated 180° around its horizontal axis, 
leaving the animal in an upside-down position and forcing it to 
hold onto the grid against its bodyweight. Healthy mice are able 
to cling to the grid for at least 20 s. The test was stopped at 60 s. 
Baseline was acquired during three measurements performed on 
separate days prior to the induction of serum-transfer arthritis.
Detection of Hind Paw Volume by 
Plethysmometry
Volumes of the hind paws were measured by plethysmometry 
(Ugo Basile Plethysmometer 7140, Comerio, Italy). Both 
mechanical pain threshold and paw volume measurements were 
carried out on the same days: three times prior to the induction 
of arthritis and on days 3, 5, and 7 thereafter. Esthesiometry was 
always performed first followed by plethysmometry. Baseline 
volume is the average of three measurements from before the 
induction of arthritis. Data are expressed in cubic centimeters.
Arthritis Score
The extent of edema formation and hyperemia of the hind limbs 
were evaluated on days 3, 5, and 7 according to a semiquantitative 
clinical score system (0–1.5, healthy condition; 1.5–2.5, minimal 
signs of disease; 2.5–4, mild inflammation; 4–7, moderate 
inflammation; and 7–10, severe inflammation) (Jakus et al., 2010; 
Botz et al., 2014).
Detection of Inflammatory Cytokines
Cytokine measurements were performed on samples of 
subcutaneous flush fluid acquired from hind paws as described 
by Kovács et al. (2014). Briefly, after induction of arthritis, 
on day 3, mice were anesthetized with ketamine/xylazine 
FIGURE 1 | Schematic representation of experimental animal groups and treatments of the study.
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(100/10 mg kg−1) and were sacrificed via cervical dislocation. 
Subcutaneous tissue of the hind paws was flushed immediately 
with 1  mL of ice-cold PBS solution supplemented with 
10  mmol  L−1 of EDTA (pH 7.5) and 20  mmol  L−1 of HEPES 
(pH 7.4). Samples were then snap frozen in liquid nitrogen 
and were stored at −80°C. Quantitative determination of IL-1β, 
KC, MIP-1α, and MIP-2 concentrations from the samples 
were performed using MILLIPLEX MAP Mouse Cytokine/
Chemokine Magnetic Bead Panel—Immunology Multiplex 
Assay (Merck Millipore, Billerica, MA, USA). A Luminex 100 
device was used for the measurement, and the interpretation of 
data was performed with the Luminex 100 IS software.
Histological Evaluation
Tibiotarsal joints were harvested on day 7. Samples were fixed 
in 4% buffered paraformaldehyde and then decalcified and 
embedded in paraffin. Sections of 3–5  μm were produced 
and stained with hematoxylin and eosin (Szabo et al., 2005). 
Histopathological changes were scored (0–3) by a blinded 
independent expert. Factors taken into consideration were the 
following: cartilage destruction, mononuclear cell infiltration, 
synovial cell proliferation, fibroblast number, and collagen 
deposition. A composite arthritis score (ranging 0–12) was 
created (Botz et al., 2014).
Statistical Analysis
Data are presented as mean  ±  standard error of the mean. 
Results were analyzed by one-way analysis of variance (ANOVA) 
followed by Tukey’s, Dunnett’s, or Bonferroni’s test. Data of SOM 
release were analyzed by Kruskal–Wallis test due to deviation 
from normal distribution in various tests. Scatterplots of data 
on mechanical pain threshold, arthritis score, suspension time, 
and hind paw volume show all individual data points. Box plots 
on histological scores show median values (horizontal line), 
minimal and maximal values (whiskers), and the 25th and 75th 
percentiles (box). Histological score values were analyzed by 
Kruskal–Wallis test followed by Dunn’s test. Concentration–
response curves were fitted with GraphPad Prism 5.0 using a 
four-parameter equation.
RESULTS
Addition of Hypochlorous Acid to GYY4137 
Leads to Formation of Polysulfide
Sulfide was released from acidified solution of GYY4137. The 
GYY4137 solution released 328.1  ±  39.33  μmol  L−1 of sulfide 
after 90-min incubation with citrate buffer (pH 3.0). Addition 
of 100 μmol L−1 of hypochlorous acid resulted in the formation 
of 77.15 ± 9.85 μmol L−1 of POLY (n = 18, data of six different 
experiments). Incubation of GYY4137 solution with equal 
volume of hydrochloric acid (1 mmol L−1) for 120 min resulted 
in the release of 147.3 ± 15.29 μmol L−1 of sulfide (n = 19, data 
of four different experiments). Treatment of CHO cells with 
sodium sulfide nonahydrate solution elicited calcium responses 
only at extremely supraphysiological concentrations. EC50 values 
in CHO cells expressing human TRPA1 ion channels and in ones 
lacking the channel were 6.14 and 9.77 mmol L−1, respectively 
(n = 5–7, data from four experiments; Figure 2A). No calcium 
influx was detected below 1  mmol  L−1. Addition of GYY4137 
to CHO cells with human TRPA1 up to 1  mmol  L−1 did not 
induce any calcium signals (n = 5, data from four experiments; 
Figure 2B). POLY (10 μmol L−1) activated CHO cells expressing 
human TRPA1. TRPA1 activation by POLY was prevented by 
HC-030031 (50 μmol L−1) and was absent in cells not expressing 
the ion channel (n = 12, each data point represents ×104 cells, 
Figure 2C). We investigated if POLY produced in GYY4137 
solution acidified with hydrochloric acid (see above) by the 
addition of hypochlorous acid activates TRPA1 in CHO cells. 
Responses to TRPA1 agonist allyl isothiocyanate (100 μmol L−1) 
were used as positive control. Neither GYY4137 solution 
acidified with hydrochloric acid nor hypochlorous acid produced 
calcium influx compared with allyl isothiocyanate. On the other 
hand, the combination of acidified GYY4137 and hypochlorous 
acid induced a similar calcium response to that seen with allyl 
isothiocyanate. The calcium signal was absent if CHO cells not 
expressing TRPA1 ion channel were used (n = 5–8, Figure 2D).
Sodium Polysulfide Stimulates Somatostatin 
Release From Nociceptor Nerve Endings in 
a TRPA1-Dependent Manner
Skin flaps of TRPA1 WT mice responded to stimulation with 
10  μmol  L−1 of POLY by releasing 0.1407  ±  0.044  fmol  mg−1 
of somatostatin-like immunoreactivity (SOM-LI). Treatment 
of the samples with 50  μmol  L−1 of HC-030031 and genetic 
lack of TRPA1 ameliorated SOM liberation (0.1407 ± 0.044 vs. 
0.0279 ± 0.017 and 0.0386 ± 0.012 fmol mg−1, n = 12, data from 
three separate experiments, Figure 3). Stimulation of skin 
samples with sodium sulfide nonahydrate up to 1 mmol L−1 did 
not provoke comparable SOM secretion (data are not shown).
GYY4137 Aggravates Mechanical 
Hyperalgesia in Arthritic TRPA1 KO Animals 
and Ameliorates It in TRPA1 WT Animals
K/BxN serum decreased the mechanical pain threshold in 
vehicle- or GYY4137-treated TRPA1 WT and KO mice (WT, 
BxN, vehicle treated, n = 7; WT, BxN, GYY4137 treated, n = 7; 
WT, K/BxN, vehicle treated, n  =  9; WT, K/BxN, GYY4137 
treated, n = 9; KO, BxN, vehicle treated, n = 9; KO, BxN, GYY4137 
treated, n = 6; KO, K/BxN, vehicle treated, n = 9; WT, K/BxN, 
GYY4137 treated, n = 10) compared with the non-arthritogenic 
control mice (Figures 4B, C). On day 3, GYY4137 aggravated 
mechanical nociception in arthritic TRPA1 KO animals than did 
both vehicles of GYY4137 in TRPA1 KO animals and TRPA1 WT 
GYY4137-treated ones (6.43 ± 0.33 vs. 7.43 ± 0.29 g in TRPA1 
KO vehicle treated and vs. 7.59 ± 0.25 g in TRPA1 WT GYY4137 
treated; Figure 4A). On day 7, GYY4137 treatment ameliorated 
mechanical pain in TRPA1 WT animals compared with KO ones 
(6.15 ± 0.36 and 4.52 ± 0.15 g in GYY4137-treated TRPA1 WT 
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and KO mice; Figure 4C). Neither GYY4137 nor genetic lack of 
TRPA1 altered mechanical pain threshold in animals injected 
with non-arthritogenic BxN serum (Figures 4A–C).
GYY4137 Lowers Arthritis Score in TRPA1 
WT Animals
Condition of the hind limbs was assessed based on a 
semiquantitative clinical scoring system (0–1.5, healthy; 1.5–
2.5, minimal signs of disease; 2.5–4, mild inflammation; 4–7, 
moderate inflammation; 7–10, severe inflammation) described 
earlier by Jakus et al. (Jakus et al., 2010; Horváth et al., 2017). 
The condition of the hind limbs deteriorated in all K/BxN 
serum-treated mice (WT, BxN, vehicle treated, n = 7; WT, BxN, 
GYY4137 treated, n = 7; WT, K/BxN, vehicle treated, n = 9; WT, 
K/BxN, GYY4137 treated, n = 9; KO, BxN, vehicle treated, n = 9; 
KO, BxN, GYY4137 treated, n = 6; KO, K/BxN, vehicle treated, 
n = 9; WT, K/BxN, GYY4137 treated, n = 10; Figures 4D–F). The 
score of TRPA1 WT vehicle-treated mice undergoing arthritis was 
higher on day 5 than that of their GYY4137-treated counterparts 
(7.97 ± 0.66 vs. 5.58 ± 0.67; Figure 4E). The difference between 
GYY4137-treated TRPA1 WT and KO animals with serum-
transfer arthritis stresses the beneficial effect of the drug in WT 
mice (5.58 ± 0.67 vs. 8.43 ± 0.51; Figure 4E). Neither GYY4137 
nor TRPA1 KO genotype influenced arthritis score in mice 
injected with control BxN serum (Figures 4D–F).
FIGURE 2 | Polysulfide produced by hypochlorous acid out of sulfide released from acidified GYY4137 activates TRPA1 ion channels in CHO cells. (A) Sodium 
sulfide nonahydrate did not activate human TRPA1 ion channels expressed in CHO cells at physiological concentrations indicated by Fluo-4 AM fluorescence. 
EC50 values of TRPA1-expressing and non-expressing cells were 7.68 and 9.87 mmol L−1, respectively (n = 5–7, dotted lines show EC50 values). (B) GYY4137 
did not elicit calcium influx in TRPA1-expressing CHO cells (n = 5). (C) Changes of [Ca2+]i of Fluo-4 AM-loaded CHO cells expressing human TRPA1 ion channels 
upon addition of sodium polysulfide (10 μmol L−1). Ca2+ concentration is characterized by increased fluorescence compared with dye-loaded unstimulated cells. 
Cell expressing human TRPA1 showed increased Ca2+ concentration in response to polysulfide. The reaction was prevented by treatment with HC-030031 
(50 μmol L−1) and lack of TRPA1 channels (n = 12, each data point represents ·104 cells. *p < 0.05 vs. 10 μmol L−1 of sodium polysulfide in TRPA1-expressing CHO 
cells). (D) Polysulfide produced by adding hypochlorous acid (616 μmol L−1) to acidified GYY4137 (7.95 mmol L−1 of GYY4137 plus equal volume of 1 mmol L−1 
of hydrochloric acid) activates human TRPA1 ion channels expressed in CHO cells similarly to allyl isothiocyanate (100 μmol L−1). Calcium influx was not detected 
in cells lacking the ion channel. Neither acidified GYY4137 nor hypochlorous acid alone induced calcium signals (n = 5–8, ap < 0.05 vs. 100 μmol L−1 of allyl 
isothiocyanate, pp < 0.05 vs. acidified GYY4137 mixed with hypochlorous acid).
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Genetic Lack of TRPA1 Impairs Hanging 
Performance in Mice Injected With 
BxN Serum Irrespective of GYY4137 
Administration
The ability of arthritic mice to keep their suspended position 
was severely impaired in all groups regardless of genotype or 
treatment on day 7 and in TRPA1 WT animals on day 5 (WT, 
BxN, vehicle treated, n = 9; WT, BxN, GYY4137 treated, n = 7; 
WT, K/BxN, vehicle treated, n  =  9; WT, K/BxN, GYY4137 
treated, n = 9; KO, BxN, vehicle treated, n = 9; KO, BxN, GYY4137 
treated, n = 6; KO, K/BxN, vehicle treated, n = 9; WT, K/BxN, 
GYY4137 treated, n  =  10; Figures 4H, I). TRPA1 KO mice 
injected with inactive BxN serum exhibited statistically shorter 
suspension on days 5 and 7 when treated with vehicle than the 
respective TRPA1 WT groups (58.89 ± 1.11 vs. 20.3 ± 4.2 s and 
58.57 ± 1.43 vs. 21.33 ± 3.93 s in non-arthritic TRPA1 WT vs. KO 
animals treated with vehicle on day 5; p < 0.001; 59.89 ± 0.11 vs. 
25.74 ± 4.71 s and 59.86 ± 0.14 vs. 22.83 ± 7.45 s in BxN serum-
injected TRPA1 WT vs. KO mice treated with vehicle on day 7; 
Figures 4H, I).
GYY4137 Does Not Influence Body 
Weight and Hind Paw Volume Detected 
by Plethysmometry
Arthritis led to weight loss in all animal groups until day 7 (data 
are not shown). Neither differences of treatment nor those of 
genotype revealed any influence on the course of body weight 
changes. This was true as well in non-arthritic animals treated 
with BxN serum.
Swelling developed in the hind paws of all groups of arthritic 
mice (TRPA1 WT, BxN, vehicle treated, n = 7; TRPA1 WT, BxN, 
GYY4137 treated, n  =  7; TRPA1 WT, K/BxN, vehicle treated, 
n = 9; TRPA1 WT, K/BxN, GYY4137 treated, n = 9; TRPA1 KO, 
BxN, vehicle treated, n = 9; TRPA1 KO, BxN, GYY4137 treated, 
n  =  6; TRPA1 KO, K/BxN, vehicle treated, n  =  9; TRPA1 WT, 
K/BxN, GYY4137 treated, n = 10; Figures 4J–L). Neither genetic 
constitution nor treatment with GYY4137 influenced paw 
swelling in K/BxN serum-injected arthritic and BxN-injected 
control mice (Figures 4J–L).
Sst4 Receptors Do Not Mediate Protective 
Effects of GYY4137 in Serum-Transfer 
Arthritis
No differences in mechanical pain threshold, hanging 
performance, arthritis score, or body weight were found between 
GYY4137-treated sst4 WT and KO mice undergoing K/BxN 
arthritis. Similarly, no influence of the genetic lack of sst4 receptor 
was detected in arthritic mice receiving vehicle of GYY4137 
(Supplementary Figure 1; WT, BxN, vehicle treated, n = 5; WT, 
BxN, GYY4137 treated, n = 5; WT, K/BxN, vehicle treated, n = 5; 
WT, K/BxN, GYY4137 treated, n = 6; KO, BxN, vehicle treated, 
n  =  5; KO, BxN, GYY4137 treated, n  =  5; KO, K/BxN, vehicle 
treated, n = 7; WT, K/BxN, GYY4137 treated, n = 9).
GYY4137 Treatment Increases Neutrophil 
Granulocyte Accumulation and Plasma 
Extravasation in Arthritic TRPA1 KO Mice
Neutrophil cell accumulation characterized by luminol 
bioluminescence indicating MPO activity was measured 
before serum transfer and then 2 and 6  days later. Daily 
treatment with GYY4137 elevated bioluminescence at day 2 
in TRPA1 KO animals compared with TRPA1 WT GYY4137-
treated mice and with TRPA1 KO vehicle-treated ones as well 
(n = 9–10 mice; 8.79 · 105 ± 8.03 · 104 vs. 4.94 · 105 ± 6.74 · 104 
and 5.19  ·  105  ±  6.04  ·  104  photons  s−1; Figures 5A, B). These 
data suggest that H2S aggravates accumulation of neutrophil 
granulocytes in TRPA1 KO animals at day 2—when the 
involvement of these cells is maximal in the arthritic reaction—
but does not influence cellular inflammation in WT mice. At 
day 6, there is no more participation of neutrophil cells in the 
foreground of serum-transfer arthritis. Plasma extravasation 
detected as IR-676 fluorescence in tissues was aggravated by 
GYY4137 injections in TRPA1 KO animals in relation to TRPA1 
WT GYY4137-treated mice and to TRPA1 KO vehicle-treated 
animals at both 2  days (n  =  9–10 mice; 4.87  ·  109  ±  2.73  ·  108 
vs. 3.37  ·  109  ±  2.3  ·  108 and 3.65  ·  109  ±  2  ·  108  (photons  s−1)
(μW  cm−2)−1; Figures 6A, B) and 6  days (p  <  0.001 and 
p  <  0.01; 7.89  ·  109  ±  4.58  ·  108 vs. 4.76  ·  109  ±  3.89  ·  108 and 
6.16 · 109 ± 3.91 · 108 (photons s−1)(μW cm−2)−1; Figures 6A, B). 
According to our findings, the rate of ongoing plasma 
extravasation—detected by fluorescence imaging—was elevated 
by H2S in TRPA1 KO animals at both days 2 and 6 but was left 
unaffected in WT ones.
Genetic Lack of sst4 Somatostatin 
Receptor Does Not Influence 
Myeloperoxidase Enzyme Activity and 
Plasma Extravasation in Arthritic Mice
No difference in MPO activity detected by luminescence 
imaging was recorded between arthritic sst4 receptor WT and 
KO GYY4137-treated animals. No participation of the receptor 
FIGURE 3 | Sodium polysulfide (10 μmol L−1) releases somatostatin 
from sensory nerve endings of isolated skin flaps of TRPA1 WT mice. 
Somatostatin release is inhibited by HC-030031 (50 μmol L−1) and genetic 
lack of the ion channel (n = 12, *p < 0.05 vs. 10 μmol L−1 of sodium 
polysulfide in TRPA1 WT samples).
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showed up when comparing sst4 WT and KO mice receiving 
vehicle of GYY4137. Similar data were generated when detecting 
plasma extravasation by fluorescence imaging (Supplementary 
Figure 2; WT, BxN, vehicle treated, n = 5; WT, BxN, GYY4137 
treated, n = 5; WT, K/BxN, vehicle treated, n = 5; WT, K/BxN, 
GYY4137 treated, n = 6; KO, BxN, vehicle treated, n = 5; KO, BxN, 
GYY4137 treated, n = 5; KO, K/BxN, vehicle treated, n = 7; WT, 
K/BxN, GYY4137 treated, n = 9).
FIGURE 4 | GYY4137 aggravates mechanical hyperalgesia of TRPA1 KO mice and ameliorates arthritis score of TRPA1 WT animals with K/BxN serum-transfer 
arthritis. Mechanical pain threshold of the hind paws (expressed in g) of GYY4137-treated (50 mg kg−1 day−1) and vehicle-treated TRPA1 WT and KO mice 
undergoing K/BxN arthritis on days (A) 3, (B) 5, and (C) 7. Semiquantitative clinical scores of GYY4137- and vehicle-treated TRPA1 WT and KO animals affected 
by serum-transfer arthritis on days (D) 3, (E) 5, and (F) 7. Time to failure of GYY4137- and vehicle-treated TRPA1 WT and KO mice having K/BxN arthritis in 
suspension test expressed in seconds on days (G) 3, (H) 5, and (I) 7. Hind paw volume detected by plethysmometry expressed in cm3 in GYY4137- and vehicle-
treated TRPA1 WT and KO mice undergoing K/BxN arthritis on days (J) 3, (K) 5, and (L) 7. Whiskers show SEM; lines denote mean values, n = 9–10 arthritic mice 
per group and n = 6–9 non-arthritic mice per group. *p < 0.05 vs. indicated group. #p < 0.05 vs. BxN serum-treated animals.
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GYY4137 Elevates MIP-2 Level in Inflamed 
Hind Paws of TRPA1 KO Mice
Serum-transfer arthritis did not affect concentrations of IL-1β, 
KC and MIP-1α in the subcutaneous flushing fluid of the hind 
paws (n = 12–16). In case of MIP-2, larger concentrations were 
measured in TRPA1 KO GYY4137-treated animals compared 
with WT GYY4137-treated ones—despite remarkably large 
standard deviation of data (16.31 ± 9.14 vs. 151.8 ± 50.93 pg mL−1 
in TRPA1 WT and KO GYY4137-treated mice; Figure 7).
GYY4137 Ameliorates Histological 
Cartilage Destruction in TRPA1 
Wild-Type Animals
Cartilage destruction score was lowered by GYY4137 
(50 mg kg−1 day−1 i.p.) in TRPA1 WT arthritic mice compared 
with vehicle-treated ones (1.063  ±  0.22 vs. 0.3125  ±  0.13, 
n = 8, Figures 8A, B). No difference of cartilage damage was 
noted in TRPA1 KO animals. Other histological parameters 
(mononuclear cell infiltration, synovial hyperplasia, fibroblast 
FIGURE 5 | GYY4137 increases MPO activity in arthritic tibiotarsal joints of TRPA1 KO mice. (A) MPO activity in inflamed tibiotarsal joints of GYY4137-
treated (50 mg kg−1 day−1 i.p.) and vehicle-treated TRPA1 WT and KO animals undergoing K/BxN arthritis on days 2 and 6 shown as emitted photons s−1. 
(B) Representative bioluminescence images illustrating MPO activity characterized by luminol bioluminescence in tibiotarsal joints of GYY4137- and vehicle-treated 
TRPA1 WT and KO animals undergoing K/BxN arthritis. Data are shown as mean ± SEM of n = 9–10 mice per group. *p < 0.05 vs. GYY4137-treated TRPA1 WT 
mice. #p < 0.05 vs. TRPA1 KO animals treated with vehicle of GYY4137.
FIGURE 6 | GYY4137 exacerbates plasma extravasation in arthritic tibiotarsal joints of TRPA1 KO mice. (A) Edema formation characterized by extravasation of 
micellar fluorescent IR-676 dye in tibiotarsal joints of GYY4137-treated (50 mg kg−1 day−1 i.p.) and vehicle-treated TRPA1 WT and KO mice undergoing K/BxN 
arthritis on days 2 and 6 expressed as (photons s−1)(μW cm−2)−1. (B) Representative fluorescence images showing plasma protein extravasation characterized 
by extravasation of micellar IR-676 dye in tibiotarsal joints of GYY4137- and vehicle-treated TRPA1 WT and KO mice undergoing K/BxN arthritis. Data are 
shown as mean ± SEM of n = 9–10 mice per group. *p < 0.05 vs. GYY4137-treated TRPA1 WT mice. #p < 0.05 vs. TRPA1 KO animals treated with vehicle 
of GYY4137.
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accumulation and collagen deposition, and the composite 
score) did not change in vehicle- or GYY4137-treated or 
animals of any genotype. Sst4  receptor WT animals treated 
with GYY4137 exhibited elevated fibroblast cell count and 
collagen deposition in comparison to vehicle-treated ones 
(Supplementary Figure 3).
DISCUSSION
The main novel finding of this study is that the presence or absence 
of functional TRPA1 channels determines pronociceptive, pro-
inflammatory, or, conversely, analgesic and anti-inflammatory 
effects of sulfide. Mice undergoing K/BxN serum-transfer arthritis 
and lacking functional TRPA1 receptors showed more severe 
mechanical hyperalgesia, more expressed plasma extravasation, 
and MPO activity in the inflamed limb, as well as increased MIP-2 
concentration in the affected paws when administered GYY4137. 
Alternatively, the slow-releasing sulfide donor ameliorated 
hyperalgesia, arthritis score, and histological cartilage destruction 
in TRPA1 WT animals. Another interesting point is that the 
protective effect was not mediated directly by sulfide itself but by 
polysulfides being formed out of it.
The protective role of TRPA1-mediated GYY4137 effect is 
pronounced by DPA measurement. WT animals showed elevated 
mechanical pain threshold, but we detected aggravated reaction in 
KO mice. K/BxN serum proved to be arthritogenic in all examined 
genotypes. GYY4137 caused significant reduction of the arthritis on 
day 5 in TRPA1 WTs. Interestingly, in our study, TRPA1 KO animals 
injected with non-arthritogenic BxN serum exhibited shorter 
time to failure than did their WT counterparts when suspended 
upside-down irrespective of GYY4137 or vehicle administration. 
Muscle cramps of athletes upon isometric strain might resemble a 
similar situation. TRPA1 and transient receptor potential vanilloid 
1 (TRPV1) agonists prevent such cramps, supporting our findings 
(Craighead et al., 2017). Lee and colleagues reported on deteriorated 
motor performance of TRPA1 KO mice (Lee et al., 2017).
In the hands of other authors, GYY4137 had an anti-
inflammatory action in CFA-induced murine arthritis. GYY4137 
inhibited mediator release from activated human synoviocytes 
and articular chondrocytes as well (Fox et al., 2012; Li et al., 2013). 
FIGURE 7 | GYY4137 elevates MIP-2 concentration in inflamed paws of 
TRPA1 KO mice. Concentrations of IL-1β, KC, MIP-1α, and MIP-2 in lavage 
fluid of the subcutaneous tissue of the inflamed hind paws of GYY4137-
treated (50 mg kg−1 day−1 i.p.) and vehicle-treated TRPA1 WT and KO mice 
undergoing K/BxN arthritis measured at day 3. Data are mean ±  SEM of 
n  =  6–8 mice per group, *p < 0.05 vs. GYY4137-treated TRPA1 WT animals.
FIGURE 8 | GYY4137 decreases cartilage destruction in tibiotarsal joints of arthritic TRPA1 WT mice. (A) Cartilage destruction score of tibiotarsal joints of GYY4137-
treated (50 mg kg−1 day−1 i.p.) and vehicle-treated TRPA1 WT and KO mice undergoing K/BxN arthritis. Samples were taken on day 7. Boxes range between the 
25th and 75th percentiles, horizontal lines denote medians, and whiskers extend from minimal to maximal values. n = 8, *p < 0.05 vs. TRPA1 WT animals treated 
with vehicle of GYY4137. Kruskal–Wallis test followed by Dunn’s test. (B) Representative histological images illustrating damage of cartilage in hematoxylin and 
eosin-stained slides of vehicle- or GYY4137-treated TRPA1 WT and KO animals injected with K/BxN serum. Images were taken at a 20× magnification.
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These previous data are in concordance with our present results: 
TRPA1 WT mice showed milder mechanical hyperalgesia, 
arthritis score, and cartilage damage in response to GYY4137.
Surprisingly, GYY4137 did not affect paw swelling measured 
by plethysmometry but increased plasma extravasation detected 
by fluorescence imaging of IR-676 in TRPA1 KO animals. 
Plethysmometry was executed on days 3, 5, and 7; fluorescence 
imaging was performed on days 2 and 6. The two methods detect 
different parameters. Plethysmometry provides information about 
the cumulative swelling—which means the equilibrium of edema 
formation and resolution—since the initiation of inflammation. 
Fluorescence imaging characterizes the actual rate or velocity of 
plasma extravasation since the administration of the fluorescent 
dye (20 min). The other seemingly conflicting data are the elevated 
MPO activity and MIP-2 content of inflamed paws despite no 
change in histological mononuclear cell accumulation score. MPO 
activity and cytokine measurements were performed on days 2 and 
3, while histological evaluation took place at a different stage of the 
inflammatory process on day 7. At this time, rather, mononuclear 
cells dominate, and neutrophil accumulation together with 
MPO activity ceases.
It might seem also contradictory how the activation of TRPA1 
channels and an increase of [Ca2+]i in nociceptors could lead 
to an opposite effect than nociception and inflammation. One 
proposed mechanism is the release of inhibitory neuropeptides 
(e.g., somatostatin). SOM release might be due to opening of 
TRPA1 or TRPV1 channels (Pethő et al., 2017; Pozsgai et al., 
2017). Elevated SOM plasma concentration in response to painful 
disease was detected in rodents and patients (Helyes et al., 2004; 
Antal et al., 2008; Suto et al., 2010). SOM possesses systemic 
antinociceptive and anti-inflammatory properties mediated by 
sst4 receptors (Helyes et al., 2004; Pintér et al., 2006; Schuelert 
et  al., 2015; Pozsgai et al., 2017). Sst4 receptors expressed in 
sensory neurons, lymphocytes, and vascular endothelial cells 
might contribute to the protective effect (Pintér et al., 2006). 
However, in the present model of arthritis, genetic lack of sst4 
receptors did not diminish protective effect of GYY4137. It has 
to be noted that protective effect of GYY4137 on mechanical pain 
threshold was also not detected in sst4 WT mice. This might be 
explained by minor genetic differences between TRPA1 and sst4 
genetically modified mouse strains together with compensatory 
changes of gene expression in genetically modified animals. 
Macrophages play a decisive role in the mediation of serum-
transfer arthritis (Christensen et al., 2016). Somatostatin sst2 
receptors dominate in human monocytes and macrophages 
(Dalm et al., 2003). Sst2 receptor agonist octreotide inhibits 
release of inflammatory cytokines (TNF-α, IL-6, and IL-15) from 
synoviocytes of RA patients, offering a plausible mechanism 
for the anti-inflammatory effect of GYY4137 (Casnici et al., 
2018). Besides, sensory neuron-derived opioid peptides might 
contribute to antinociceptive action, too (Pethő et al., 2017).
The protective effect of sulfide in the K/BxN serum-transfer 
arthritis model might be mediated by non-neuronal TRPA1 
expressed on immune and inflammatory cells. CD4+ T cells have a 
major role in the development of serum-transfer arthritis, as mutation 
of the T-cell receptor and formation of autoreactive T cells are key 
features of the model. Depletion of either neutrophil granulocytes 
or macrophages is protective against serum-transfer arthritis 
(Christensen et al., 2016). TRPA1 expression in CD4+ T cells was 
confirmed on the level of mRNA and by immunohistochemistry. 
TRPA1 channels of T lymphocytes were found to be functional 
by electrophysiological methods. Genetic abrogation of TRPA1 
exacerbated a murine model of autoimmune colitis. TRPA1 was 
found to inhibit Th1 immune response (Bertin et al., 2017). TRPA1 
was detected in murine CD4+ T cells in a model of psoriasis by 
immunohistochemistry (Kemény et al., 2018). Activation of the 
ion channel mediates a protective effect in psoriasiform dermatitis. 
Increased expression of TRPA1 was reported in peripheral blood 
leukocytes of rheumatoid arthritis patients. Antagonism of TRPA1 
aggravated inflammation and MIP-2 secretion from macrophages. 
TRPA1 agonist allyl isothiocyanate was protective against 
atherosclerosis and ameliorated MIP-2 release (Zhao et al., 2016). 
All the above findings indicate that activation of TRPA1 by sulfide 
on T lymphocytes, neutrophil granulocytes, or macrophages might 
have contributed to the anti-inflammatory effect revealed by the 
present study.
Several possible mechanisms could be supposed in the 
background of TRPA1-independent pro-inflammatory effect of 
GYY4137. Sulfide donor NaHS produced non-canonical p38/
Akt and CREB activation in human peripheral blood monocytes 
(Sulen et al., 2016). Various inflammatory animal models were 
reported to be augmented by sulfide or alleviated by disabled 
synthesis of the gasotransmitter. The signaling pathways involved 
include PI3K/Akt/Sp1, COX2, and NF-κB (Ang et al., 2011; Badiei 
et al., 2016; Gaddam et al., 2016; George et al., 2016; Liu et al., 
2016; Ahmad et al., 2017; Liu et al., 2017). Our results indicate 
that TRPA1-mediated protective effects of H2S “overwrite” 
inflammatory and pro-algesic effects mediated via other pathways. 
Detrimental effects only manifest in the absence of TRPA1.
According to our data, concentration of the chemoattractant 
MIP-2 (CXCL2) was elevated by GYY4137 in inflamed hind 
paws of arthritic TRPA1 KO animals on day 3. This finding is 
in alignment with increased MPO activity—denoting neutrophil 
granulocyte accumulation—in tibiotarsal joints of TRPA1 KO 
mice detected on day 2. MIP-2 is a chemoattractant for neutrophil 
cells and is released by monocytes, macrophages, epithelial cells, 
and hepatocytes (Qin et al., 2017). In the K/BxN serum-transfer 
arthritis model, activated neutrophils might express CXCL2 
themselves. Recruitment of neutrophil granulocytes depends 
on the expression of CXCR2, the receptor of MIP-2. Depletion 
of macrophages—an important source of MIP-2—is protective 
against serum-transfer arthritis (Christensen et al., 2016). 
Activation of TRPA1 is involved in MIP-2 secretion, too. TRPA1 
KO mice showed lowered concentration of the chemoattractant 
in a subcutaneous air pouch model (Moilanen et al., 2015).
Our data point towards GYY4137 being an “inflammation-
selective” polysulfide donor. As it was described earlier and 
confirmed by our data, sulfide release from GYY4137 increases 
dramatically at pH 3.0 (Li et al., 2008). Acidic pH was found in RA 
synovial fluid (Martínez et al., 2006). Addition of hypochlorous 
acid to the liberated sulfide rapidly yields POLY (Nagy and 
Winterbourn, 2010). We postulate that excess sulfide released 
in acidic inflamed tissues is scavenged by hypochlorite from 
neutrophil granulocytes. Lack of hypochlorite was suspected to 
GYY4137 Modulates Arthritis via TRPA1Bátai et al.
13 September 2019 | Volume 10 | Article 964Frontiers in Pharmacology | www.frontiersin.org
increase MIP-2 production of neutrophil cells (Tateno et al., 2013). 
Elevated MIP-2 concentrations were measured in subcutaneous 
flushing fluid of arthritic TRPA1 KO mice by the authors. On 
the other hand, POLY resulting from the reaction of sulfide and 
hypochlorite persulfidates TRPA1 ion channels of nociceptor 
nerve endings and might trigger protective effects. Production 
of hypochlorite by neutrophils is MPO dependent (Albrett et al., 
2018). Elevated MPO activity in GYY4137-treated TRPA1 KO 
animals suggests larger hypochlorite and POLY formation. A 
larger amount of POLY could mediate more expressed TRPA1-
independent inflammatory changes.
Inconsistent data on the effect of sulfide in inflammation 
and nociception have been published since the advent of 
sulfide research a decade ago. According to our present study, 
protective actions of the gasotransmitter are associated with 
TRPA1 receptor activation, while detrimental ones are mediated 
by other mechanisms in murine arthritis. In the present study, 
slow-releasing sulfide donor GYY4137 is an instrument to study 
the role of TRPA1 ion channel in the effects of sulfide in murine 
K/BxN serum-transfer arthritis model. Our approach provides 
hints on the importance of TRPA1 channels for the development 
and application of  sulfide therapeutics depending on whether 
amelioration of inflammation or cytotoxic effect is desired.
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